02137 騰盛博藥－Ｂ
按盘价 
1.370 -0.090 (-6.164%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -8.789% | -17.212% | -5.306% | -13.830% | -170.662% |
| 股东资金回报率 (%) | -8.847% | -17.596% | -5.538% | -14.816% | -518.984% |
| 资本运用回报率 (%) | -9.566% | -19.328% | -5.690% | -15.313% | -125.003% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | -- | N/A | -- | -- | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -1429.739% | N/A | -44769.044% | -986.135% | N/A |
| 税前边际利润率 (%) | -1194.125% | N/A | -29881.686% | -948.710% | N/A |
| 纯利率 (%) | -1196.582% | N/A | -28335.332% | -938.116% | N/A |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 60.734 X | 31.182 X | 22.109 X | 13.430 X | 12.162 X |
| 速动比率 (X) | 60.734 X | 31.182 X | 22.109 X | 13.430 X | 12.162 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 1.534% | 3.715% | 3.936% | 6.909% | 8.319% |
| 总债项 / 总资产比率 (%) | 0.378% | 1.699% | 0.099% | 0.373% | 0.598% |
| 净债项 / 总资产比率 (%) | -25.340% | -35.372% | -15.211% | -34.728% | -78.453% |
| 总债项 / 股东资金比率 (%) | 0.376% | 1.731% | 0.101% | 0.396% | 0.647% |
| 长期债项 / 股东资金比率 (%) | 0.164% | 0.870% | 0% | 0.099% | 0.378% |
| 净债项 / 股东资金比率 (%) | -25.168% | -36.033% | -15.598% | -36.872% | -84.761% |
| 净现金 / (债项) ($) | 5.98亿 | 9.57亿 | 4.86亿 | 11.78亿 | 28.33亿 |
| 每股净现金 / (债项) ($) | 0.829 | 1.309 | 0.667 | 1.620 | 3.934 |
| 总债项 / 资本运用比率 (%) | 0.384% | 1.749% | 0.103% | 0.400% | 0.649% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 应收贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 备注： | 实时报价更新时间为20/03/2026 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB -222,624 |
| 增长率 | -56.190% |
| 每股盈利/(亏损) | RMB -0.310 |
| 每股账面资产净值 (¥) | RMB 3.294 |